These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32484991)

  • 41. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: The emerging role of non-viral risk factors.
    Li W; Deng R; Liu S; Wang K; Sun J
    Liver Int; 2020 Oct; 40(10):2316-2325. PubMed ID: 32666675
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues.
    Liu CJ
    J Gastroenterol Hepatol; 2014 Jan; 29(1):26-30. PubMed ID: 24199625
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An expert consensus for the management of chronic hepatitis B in Asian Americans.
    Tong MJ; Pan CQ; Han SB; Lu DS; Raman S; Hu KQ; Lim JK; Hann HW; Min AD
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1181-1200. PubMed ID: 29479728
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HBV reactivation during direct-acting antiviral therapy in hepatitis B and C coinfected patients undergoing haemodialysis.
    Wang J; Hu C; Chen Y; Liu Z; Yu Q; Yang S; Dong J; Yang Y; Wu Y; Ren D; Yao N; Guo D; Tian Z; Zhao Y; Chen T; He Y; Liu J
    Antivir Ther; 2019; 24(2):77-84. PubMed ID: 30833515
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents.
    Chen Q; Ayer T; Adee MG; Wang X; Kanwal F; Chhatwal J
    JAMA Netw Open; 2020 Nov; 3(11):e2021173. PubMed ID: 33206188
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma.
    Huang DQ; Hoang JK; Kamal R; Tsai PC; Toyoda H; Yeh ML; Yasuda S; Leong J; Maeda M; Huang CF; Won Jun D; Ishigami M; Tanaka Y; Uojima H; Ogawa E; Abe H; Hsu YC; Tseng CH; Alsudaney M; Yang JD; Yoshimaru Y; Suzuki T; Liu JK; Landis C; Dai CY; Huang JF; Chuang WL; Schwartz M; Dan YY; Esquivel C; Bonham A; Yu ML; Nguyen MH
    J Clin Oncol; 2024 Mar; 42(7):790-799. PubMed ID: 38175991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B.
    Yuen L; Revill PA; Rosenberg G; Wagner J; Littlejohn M; Bayliss J; Jackson K; Tan SK; Gaggar A; Kitrinos K; Subramanian M; Gane E; Chan HLY; Li X; Bowden S; Locarnini S; Thompson A
    J Viral Hepat; 2020 Oct; 27(10):1061-1070. PubMed ID: 32384174
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
    Yanny BT; Latt NL; Saab S; Han S; Choi G; Kramer J; Sahota AK
    J Clin Gastroenterol; 2018; 52(10):908-912. PubMed ID: 29334502
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.
    Belli LS; Perricone G; Adam R; Cortesi PA; Strazzabosco M; Facchetti R; Karam V; Salizzoni M; Andujar RL; Fondevila C; De Simone P; Morelli C; Fabregat-Prous J; Samuel D; Agarwaal K; Moreno Gonzales E; Charco R; Zieniewicz K; De Carlis L; Duvoux C;
    J Hepatol; 2018 Oct; 69(4):810-817. PubMed ID: 29940268
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical characteristics of hepatic flare and efficacy of antiviral therapy in pregnant women with chronic hepatitis B virus infection].
    Ding Y; Sheng QJ; Zhang C; Wu YY; Yuan SY; Xia TT; An ZY; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Feb; 27(2):106-111. PubMed ID: 30818914
    [No Abstract]   [Full Text] [Related]  

  • 52. Profile of patients triply infected with HIV and the hepatitis B and C viruses in the HAART era.
    Maida I; Ríos MJ; Pérez-Saleme L; Ramos B; Soriano V; Pegram PS; Mura MS; Sánchez-Margalet V; Saldívar-Cornejo I; Wilkin A; Babudieri S; Núñez M
    AIDS Res Hum Retroviruses; 2008 May; 24(5):679-83. PubMed ID: 18462085
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epidemiology and clinical management of HIV-HBV coinfected patients in a large AIDS Reference Center in Belgium.
    Farid Y; Martin C; Delforge M; De Wit S
    Acta Clin Belg; 2019 Dec; 74(6):424-429. PubMed ID: 30513065
    [No Abstract]   [Full Text] [Related]  

  • 54. Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection.
    Jacob R; Danta M
    Expert Opin Pharmacother; 2022 Mar; 23(4):465-472. PubMed ID: 34937470
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Monitoring patients with chronic hepatitis during and after therapy].
    Colić-Cvrlje V
    Acta Med Croatica; 2005; 59(5):413-7. PubMed ID: 16381236
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Review article: the prevention of hepatitis B-related hepatocellular carcinoma.
    Lin CL; Kao JH
    Aliment Pharmacol Ther; 2018 Jul; 48(1):5-14. PubMed ID: 29722445
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis.
    Mücke MM; Backus LI; Mücke VT; Coppola N; Preda CM; Yeh ML; Tang LSY; Belperio PS; Wilson EM; Yu ML; Zeuzem S; Herrmann E; Vermehren J
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):172-180. PubMed ID: 29371017
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of antiviral therapy in the management of hepatocellular carcinoma.
    Guan YS; He Q
    Anticancer Drugs; 2013 Apr; 24(4):337-43. PubMed ID: 23388161
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
    Kawagishi N; Suda G; Onozawa M; Kimura M; Maehara O; Ohara M; Izumi T; Umemura M; Ito J; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N
    J Viral Hepat; 2017 Dec; 24(12):1098-1106. PubMed ID: 28632923
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen.
    Londoño MC; Lens S; Mariño Z; Bonacci M; Ariza X; Broquetas T; Pla A; Bartres C; Adriani MV; Rodríguez-Tajes S; Costa J; Carrión JA; Pérez-Del-Pulgar S; Forns X
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1156-1161. PubMed ID: 28206681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.